RE-ADVERTISED EXTENSION OF RFP-DAN-2020-503183 MEDICINES FOR CONVID -19 CASE MANAGEMENT
UNICEF
RE-ADVERTISED EXTENSION OF RFP-DAN-2020-503183 MEDICINES FOR CONVID -19 CASE MANAGEMENT
Request for proposal
Reference:
RFP-DAN-2020-503183
Beneficiary countries or territories:
Multiple destinations (see 'Countries' tab below)
Registration level:
Registration at Level 2
Published on:
27-Jun-2022
Deadline on:
30-Jun-2023 00:00 (GMT 1.00)
Description
Re-ADVERTISED EXTENSION OF RFP-DAN-2020-503183
Clarification Letter No.12.
New submission deadline: 30th of June 2023, (GMT+2) 23:59 (Copenhagen time)
This request for proposal is for
MEDICINES FOR CONVID -19 CASE MANAGEMENT
For specific use in managing SARS-COV-2 infected or exposed children, adolescents, women, and their families in resource-limited settings.
Wei Gu - wgu@unicef.org
51341501
-
Amprenavir
51341604
-
Rimantadine hydrochloride
51341801
-
Darunavir
51341802
-
Oseltamivir
51341803
-
Darunavir ethanolate
51341805
-
Oseltamivir phosphate
51341806
-
Sofosbuvir
51341807
-
Daclatasvir
51341901
-
Zanamivir
51341903
-
Efavirenz
51341904
-
Maraviroc
51342301
-
Valaciclovir or valacyclovir
51342304
-
Entecavir
51342305
-
Ganciclovir
51342307
-
Penciclovir
51342308
-
Valganciclovir
51342309
-
Aciclovir or acyclovir
51342310
-
Valacyclovir hydrochloride
51342311
-
Aciclovir sodium
51342313
-
Ganciclovir sodium
51342316
-
Valganciclovir hydrochloride
51342402
-
Saquinavir
51342501
-
Abacavir
51342503
-
Ribavirin
51342506
-
Abacavir sulfate
51342701
-
Atazanavir
51342702
-
Enfuvirtide
51342709
-
Interferon beta-1a
51342710
-
Interferon beta-1b
51342715
-
Peginterferon alfa-2a
51342901
-
Didanosine
51342902
-
Famciclovir
51342904
-
Vidarabine
51343002
-
Nevirapine
51343004
-
Stavudine or stavidine
51343005
-
Stavudine and lamivudine and nevirapine
51343101
-
Idoxuridine
51343110
-
Lamivudine
51343115
-
Zalcitabine
51343116
-
Azidothymidine or zidovudine
51343201
-
Raltegravir
51343203
-
Ritonavir
51343204
-
Dolutegravir
51343502
-
Cidofovir
51343509
-
Tenofovir alafenamide fumarate
51343511
-
Tenofovir disoproxil
51343702
-
Moroxydine
51343704
-
Etravirine
51343801
-
Abacavir/lamivudine
51343803
-
Efavirenz/emtricitabine/tenofovir
51343804
-
Emtricitabine/tenofovir
51343806
-
Lamivudine/zidovudine
51343809
-
Dolutegravir/Abacavir/Lamivudine
51343810
-
Darunavir/Cobicistat
51343811
-
Emtricitabine/Tenofovir Alafenamide/Bictegravir
51343811
-
Emtricitabine/Tenofovir Alafenamide/Bictegravir
51343812
-
Glecaprevir/Pibrentasvir
51343813
-
Sofosbuvir/Velpatasvir
51343814
-
Lopinavir/ritonavir
51343816
-
Lamivudine/tenofovir DF
51343820
-
Lamivudine/nevirapine/zidovudine
51343821
-
Lopinavir/ritonavir
51343822
-
Atazanavir/ritonavir
51343826
-
Sofosbuvir/Velpatasvir
51343827
-
Daclatasvir/Sofosbuvir
51343828
-
Darunavir/Ritonavir
The COVID-19 tender was changed to be valid through 30th June 2023. Please find the detail in Clarification Letter 11.
Edited on:
29-Dec-2022 10:37
Edited by:
wgu@unicef.org